LLY Eli Lilly and Company Loading...

From RMD earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
21:30
Jan 29 ◎
Mick Farrell CEO, ResMed Inc. RMD Q2 FY26 call
ResMed is seeing durable, accelerating patient adherence for CPAP when combined with GLP-1 prescriptions, evidenced by a 6.2% higher resupply rate at three years. — GLP-1 drugs are not cannibalizing CPAP; they are expanding the market and improving adherence, which supports ResMed's long-term growth.
LLY
MED

About LLY Analyst Coverage

Buzzberg tracks LLY (Eli Lilly and Company) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Mick Farrell.